Success Story: Precision Pulmonary Medicine Research Leads to NIW Approval in Just 1 Month and 16 Days

Posted by wegreened on July 29, 2026 in NIW, Medicine (Pharmaceutics, Pharmacology, Oncology, Pharmacognosy, Biomedical Engineering, Biomedicine)

Client’s Testimonial:

"Thank you so much for sharing this wonderful news! I am absolutely thrilled to see that my I-140 NIW petition has been officially approved as of June 1, 2026.

I want to express my deepest gratitude to the entire team for your professionalism, meticulous preparation, and continuous support throughout this process.”

On June 1^st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for an Attending Physician in the Field of Pulmonary Medicine (Approval Notice).

General Field: Pulmonary Medicine

Position at the Time of Case Filing: Attending Physician

Country of Origin: Taiwan

Country of Residence at the Time of Filing: Taiwan

Approval Notice Date: June 1^st, 2026

Processing Time: 1 month, 16 days (Premium Processing Requested)

Case Summary:

The client earned both an M.D. and a Ph.D. in pharmacology and built a career that combined clinical medicine, translational research, and advanced data analytics. At the time of filing, he was practicing medicine in Taiwan while conducting research aimed at improving precision treatment strategies for lung cancer, asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

North America Immigration Law Group (Chen Immigration Law Associates) presented the proposed endeavor as an effort to leverage advanced genomic profiling, real-world clinical data, and computational biology to better understand the cellular and genetic diversity within complex oncological and respiratory conditions. The ultimate goal was to identify targeted therapeutic markers and precision medicine strategies capable of improving patient survival rates while mitigating the burden of treatment-resistant diseases.

At the time of filing, the client's scholarly accomplishments included:

16 peer-reviewed journal articles

215 citations

2 papers ranking among the top 10% most-cited Clinical Medicine articles for their publication years

Rather than presenting these metrics as isolated academic milestones, the petition demonstrated that this research serves as a vital foundation for active clinical advancements. To establish national importance, the filing emphasized how the proposed endeavor directly aligned with major U.S. public health priorities. We demonstrated that severe oncological and chronic respiratory conditions affect millions of citizens nationwide and remain the leading causes of mortality. By identifying more effective, individualized treatment strategies, the client's research directly addressed these national crises, which promised to optimize patient outcomes and significantly reduce systemic healthcare expenditures.

Ultimately, this approval recognized the value of continued research aimed at improving lung cancer survival, advancing precision respiratory medicine, and reducing the burden of severe pulmonary disease through data-driven therapeutic innovation in the United States.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%